Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Weekly Current Affairs One-Liners Current Affairs 2026 plays a very important role in competitive examinations…
The FIFA World Cup 2026 has entered the most dramatic and thrilling stage of the…
National News Centre of Excellence for Human Wildlife Conflict Management Inaugurated The Centre of Excellence…
For the fifth time a row, the Indian Air Force (IAF) has clinched the third…
According to a recent report by the UN Women agency, at least one million women…
India and New Zealand have upgraded their relationship into a Strategic Partnership by launching an…